Lactoferrin is a glycoprotein naturally present in milk, and Japan has one of the most developed lactoferrin ingredient and research bases in the world, built largely around the country’s dairy industry. Brands abroad ask for a Japan-made lactoferrin product because of that depth of formulation and trial experience.
This guide is for brand owners planning a lactoferrin product made in Japan. It covers what the human trials show, who was behind them, why the delivery format matters more for this ingredient than for most, Japan’s regulatory framing, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a lactoferrin product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Japanese trials report reduced visceral fat area with enteric-coated lactoferrin, and lower everyday respiratory and systemic symptom scores with tablets held in the mouth, in trials closely linked to the companies behind the material.
| Study | Design | Reported result |
|---|---|---|
| Double-blind, placebo-controlled trial, British Journal of Nutrition 2010 (PMID 20691130) | 26 Japanese adults aged 22–60 with abdominal obesity; 300 mg/day enteric-coated bovine lactoferrin or placebo for 8 weeks | Visceral fat area decreased 14.6 cm² with lactoferrin versus 1.8 cm² with placebo (p = 0.009); body weight, BMI and hip circumference also decreased more with lactoferrin; the first author worked in the research and development division of a company |
| Randomised, double-blind, placebo-controlled trial, Nutrients 2023 (PMID 37764743) | 157 healthy adults randomised and 145 analysed (68 lactoferrin, 77 placebo); 200 mg/day bovine lactoferrin as tablets licked for a few tens of seconds and then swallowed, for 12 weeks | Combined respiratory and systemic symptom scores were significantly lower with lactoferrin during the intervention; markers of dendritic cell activity (CD86, HLA-DR) were significantly higher at 12 weeks; no adverse reactions reported; the dairy company that funded the study and supplied the test food employed five of the nine authors |
Three points to keep in view:
- Size. The visceral fat trial studied only 26 people over 8 weeks. The immune-measure trial is larger at 145 people analysed over 12 weeks, but both are short relative to how visceral fat and immune resilience change over months or years.
- Funding. The immune-measure trial was funded by the dairy company that supplied the test tablets, and five of its nine authors were company employees. The visceral fat trial’s first author worked in a company’s research and development division. That does not make the results wrong, but it is a material fact to disclose alongside any figure you cite.
- Format. The two trials used different tablets. The visceral fat trial used enteric-coated tablets; the immune-measure trial deliberately had people lick ordinary tablets before swallowing, and its authors note there is no clinical evidence for the same immune effects with enteric-coated products.
- What was measured. “Everyday respiratory and systemic symptom scores” and “visceral fat area” are specific, narrow measures — not general immunity or general weight loss.
Checked against the published abstracts on 13 October 2026.
What Japanese products say
Lactoferrin appears in Japan’s Foods with Function Claims system, with notified products addressing categories such as visceral fat and BMI.
Under the Foods with Function Claims system, the notifying business is responsible for the scientific evidence behind its stated function and submits it to the Consumer Affairs Agency before sale. Lactoferrin products have been notified in the visceral-fat and BMI categories, generally reflecting the kind of trial evidence above.
Two lessons for a brand abroad:
- A Japanese notification covers one specific, worded function at one tested amount. It is not a general licence to make broader weight-loss or immunity claims for the ingredient.
- A Japanese notification is not a global endorsement. It is a Japanese regulatory mechanism for products sold in Japan. Your label abroad follows your own market’s rules.
💬 Need an evidence summary for your regulatory adviser that separates Japanese notifications from the underlying trials? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe lactoferrin by the specific measures the trials found significant, never as a general weight-loss or immune-boosting ingredient.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for visceral fat area in a Japanese trial" | "Burns fat”, “boosts immunity”, or any disease name |
| ”Contains 200–300 mg lactoferrin per daily serving, in the format used in the cited trial" | "Clinically proven” without naming the study, its funding and its limits |
| ”Studied for everyday respiratory and systemic wellbeing” | Implying protection from any named infection or illness |
How lactoferrin is formulated
The tablet format is central to a lactoferrin specification, because the visceral fat trial used enteric coating and the immune-measure trial deliberately did not.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Enteric-coated tablet | Matches the format used in the visceral fat trial above | Coating adds cost and manufacturing steps; coating uniformity across the batch |
| Tablet held in the mouth, then swallowed | Matches the format used in the immune-measure trial above | Taste and mouthfeel matter, since the tablet stays in the mouth for a few tens of seconds |
Decisions that shape the specification:
- Format. Choose the format of the study you intend to cite. Enteric-coated tablets match the visceral fat trial; tablets held in the mouth match the immune-measure trial. Mixing the two — for example an enteric-coated product described with the immune-measure results — is a different specification from what the evidence supports.
- Source. Lactoferrin for foods is derived from bovine milk. Confirm the supplier’s purification method and purity.
- Amount per serving. Match the amount to a study you intend to cite — 200 mg/day and 300 mg/day both appear above.
- Milk allergen labelling. Lactoferrin is a milk-derived protein. Allergen labelling requirements for milk apply in most markets and must be confirmed for each one you sell in.
- Companion ingredients. Lactoferrin is sometimes combined with other ageing- or immune-focused ingredients. Each needs its own check against Japanese food law.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Bovine lactoferrin is a well-established food ingredient in Japan with existing Foods with Function Claims notifications. Companion botanicals in a combined formula need their own check, since some botanicals sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and compare with our lactic acid bacteria and NMN guides if you are building a combined formula.
Before you ask for a quotation
A factory can quote accurately once the source, the format, the amount and the packaging are fixed.
- Lactoferrin source, purity and certificate of analysis
- Format (enteric-coated, or a tablet held in the mouth) and the study it matches
- Amount per serving and servings per pack
- Dosage form
- Milk allergen labelling for each market you sell in
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made lactoferrin product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does lactoferrin reduce visceral fat?
A 2010 Japanese trial in 26 adults with abdominal obesity found enteric-coated lactoferrin at 300 mg/day reduced visceral fat area significantly more than placebo over 8 weeks. It is a small, short, industry-linked trial in a specific population, so describe it as studied for visceral fat area, not as a general fat-loss product.
2. Does lactoferrin support everyday immune health?
A 2023 trial that randomised 157 healthy adults and analysed 145 found lower combined respiratory and systemic symptom scores and higher markers of dendritic cell activity with 200 mg/day lactoferrin over 12 weeks. The tablets were licked for a few tens of seconds before swallowing, and the dairy company that funded the study employed five of its nine authors. Describe it by that specific, studied outcome.
3. Does lactoferrin need enteric coating?
It depends on the evidence you plan to cite. The visceral fat trial used enteric-coated tablets, while the immune-measure trial used ordinary tablets licked before swallowing, and its authors state there is no clinical evidence for those immune effects with enteric-coated products. Match the format to the study, as well as the dose.
4. Is lactoferrin a milk allergen?
Yes. Lactoferrin is derived from bovine milk and needs milk allergen labelling in most markets. Confirm the requirement for each country you plan to sell in.
5. Is lactoferrin permitted in foods in Japan?
Yes. Bovine lactoferrin is a well-established Japanese food ingredient, with existing Foods with Function Claims notifications in categories such as visceral fat and BMI.
Sources: “Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets”, British Journal of Nutrition 2010, 104(11):1688-1695 (PMID 20691130); “Effects of Bovine Lactoferrin on the Maintenance of Respiratory and Systemic Physical Conditions in Healthy Adults”, Nutrients 2023, 15(18):3959 (PMID 37764743, PMC10537451); Consumer Affairs Agency notifications for Foods with Function Claims. Checked on 13 October 2026.